Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia;El uso de agentes anticolinérgicos inhalados y la retención urinaria aguda en hombres con síntomas del trayecto urinario bajo o hiperplasia benigna de la próstata

Annals of Pharmacotherapy

Volumn 46, Issue 9, 2012, Pages 1245-1249

  Vande Griend Dr , Joseph P ^a   Linnebur, Sunny A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Inhaled anticholinergics; Ipratropium; Tiotropium; Urinary retention

Indexed keywords

IPRATROPIUM BROMIDE PLUS SALBUTAMOL; TIOTROPIUM BROMIDE;

ACUTE URINARY RETENTION; ARTICLE; CASE CONTROL STUDY; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DRUG INDICATION; DRUG LABELING; DRUG MEGADOSE; DRUG USE; HUMAN; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MEDLINE; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; URINE RETENTION;

ADMINISTRATION, INHALATION; CHOLINERGIC ANTAGONISTS; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; URINARY RETENTION;

EID: 84865842956     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R282     Document Type: Article

References (19)

1. Global Initiative for Chronic Obstructive Lung Disease, Revised 2011. www.goldcopd.org (accessed 2012 Apr 20).
2. Product information. Spiriva (tiotropium). Ridgefield, CT: Boehringer Ingelheim, November 2011.
3. Product information. Combiven (ipratropium and albuterol). Ridgefield, CT: Boehringer Ingelheim, September 2010.
4. Brown JH, Laiken N. Muscarinic receptor agonists and antagonists. In: Chabner BA, Brunton LL, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011. www.accesspharmacy.com/content.aspx?aID=16660596 (accessed 2012 Jun 7).
5. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008;31:373-88.
6. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
7. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999;162:376-82.
8. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, van der Meulen JH. Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ 2007;335:1199-202.
9. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
10. Pras E, Stienlauf S, Pinkhas J, Sidi Y. Urinary retention associated with ipratropium bromide. DICP 1991;25:939-40.
11. Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989;65:260-1.
12. Miyazaki H, Suda T, Otsuka A, et al. Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia. Pulm Pharmacol Ther 2008;21:879-83.
13. Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011;171: 914-20.
14. Afonso AS, Verhamme KM, Stricker BH, Sturkenboom MC, Brusselle GG. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU Int 2011;107:1265-72.
15. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61: 854-62.
16. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703.
17. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
18. Pedone C, Incalzi RA. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185; author reply 7.
19. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364: 1093-103.